Skip to main content
Clinical Trials/NCT04124458
NCT04124458
Not yet recruiting
Not Applicable

A Comparison of Pain Control AND Quality of Life Improvement Between Occipital Nerve Block And Occipital Nerve Radiofrequency Ablation: A Double-Blind Single Center Prospective Study

Allevio Pain Management Clinic0 sites70 target enrollmentJanuary 2, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Occipital Neuralgia
Sponsor
Allevio Pain Management Clinic
Enrollment
70
Primary Endpoint
Quality of life assessment: Short Form Brief Pain Inventory (BPI-SF)
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

This is a randomized, double blind, single-center, clinical trial. The study will be conducted over a period of 6 months. The study will be conducted at the Allevio Pain Clinic, Toronto, Canada.

Detailed Description

During the first visit the investigator will assess potential subject's eligibility. Screening and recruitment, and randomization, and administer questionnaires will be performed by research coordinator. Study informed consent form (ICF) can be signed on the RF procedure day. If additional visits will be required to finalize the procedures related to the first visit they will be scheduled accordingly. After randomization the qualified participants will be scheduled for their bilateral Occipital RF or bilateral Occipital Block. Participants will be asked to complete the follow-up questionnaires at baseline, 3 and 6 months. On their last study visit, participants will have an exit interview, in addition to completing study measures.

Registry
clinicaltrials.gov
Start Date
January 2, 2023
End Date
December 31, 2025
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Allevio Pain Management Clinic
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age 18-90
  • Confirmed diagnosis of occipital headaches, patients with concurrent other types of headaches will not be excluded (except undiagnosed headaches)
  • Duration of occipital headaches \> 3 months

Exclusion Criteria

  • Non-English speakers;
  • Refusal to sign informed consent;
  • Allergy to medications which will be used in the study;
  • Concurrent undiagnosed headaches
  • Current brain tumors
  • Current known tumors with known metastasis in other organs
  • Occipital blocks within the last 3 months
  • Currently receiving treatment with Botox for migraine.
  • Patient has RF of occipital nerve/s within the last year

Outcomes

Primary Outcomes

Quality of life assessment: Short Form Brief Pain Inventory (BPI-SF)

Time Frame: Change from baseline BPI-SF at 6 months

measured by Short Form Brief Pain Inventory (BPI-SF), between minimum of zero and maximum of ten

Secondary Outcomes

  • Quality of life assessment: General Anxiety Disorder Questionnaire (GAD)(Baseline, every 3 months up to 6 months)
  • Quality of life assessment: Patients self-reported perceived duration of effect (PSPDE)(Baseline, every 3 months up to 6 months)
  • Quality of life assessment: Global Improvement and Satisfaction score measured by PGIC)(Baseline, every 3 months up to 6 months)
  • At Least of 30% decrease in the pain score(Baseline, every 3 months up to 6 months)
  • Quality of life assessment(Baseline, every 3 months up to 6 months)

Similar Trials